The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because it will stifle innovation and chances are these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Follow-on biologics are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

Full Story:

Related Summaries